Faculty introduction, disclosures

Introduction content: cursory refresher and review Epidemiology: statistics by age and severity  Diagnosing and risk-stratifying ALL  Clinical features, presentation, and histopathology

Updates in pediatric treatment in ALL  The role of MRD testing   Importance of high-sensitivity testing  Using MRD in decision making  NCCN guideline recommendations for pediatric ALL Induction therapy options  Managing detectable MRD  Role of hematopoietic stem cell transplant  Novel treatment options for ALL in remission with detectable MRD or relapsed disease  Limitations of chemotherapy  Bispecific antibodies  CAR-T  Role of hematopoietic stem cell transplant  Additional considerations: optimizing and managing asparaginase therapy  Updates in adjunct therapies and supportive care  Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Explain the pathophysiology of ALL and how it pertains to therapeutic targets when treating children and adolescents.
• Describe the risk and benefit profiles and place in therapy of conventional and novel treatments for ALL in children and adolescents.
• Select a post-induction or post-reinduction treatment regimen for a pediatric patient, taking relevant biomarkers and previous clinical response into account.
• Develop a treatment plan for a pediatric patient with ALL after relapse.

ACCME Activity #202555680

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Stephen P. Hunger, MD, Chief, Division of Pediatric Oncology, Children’s Hospital of Philadelphia, has received financial compensation for consulting work from Amgen, Jazz Pharmaceuticals, Novartis and Servier and is a stockholder of Amgen.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Jazz Pharmaceuticals. 

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version